Most Claims Survive In Qui Tam Case Alleging False Claims, Kickbacks For Anti-Fungal Drug
(March 3, 2016, 1:07 PM EST) -- PHILADELPHIA — A Pennsylvania federal judge on March 1 denied dismissal of most claims by two whistle-blowers who allege that Pfizer Inc. fraudulently obtained approval of the anti-fungal drug Vfend and marketed it for off-label uses that led to submission of false claims (United States of America, ex rel. Catherine A. Brown, et al. v. Pfizer, Inc., No. 05-6795, E.D. Pa.; 2016 U.S. Dist. LEXIS 25723).